Found: 43
Select item for more details and to access through your institution.
Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia: An Open-Label Extension Study of a Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 7, p. e2421495, doi. 10.1001/jamanetworkopen.2024.21495
- By:
- Publication type:
- Article
Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
- Published in:
- Journal of Women's Health (15409996), 2024, v. 33, n. 4, p. 480, doi. 10.1089/jwh.2023.0037
- By:
- Publication type:
- Article
Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
- Published in:
- International Journal of Neuropsychopharmacology, 2024, v. 27, n. 2, p. 1, doi. 10.1093/ijnp/pyad067
- By:
- Publication type:
- Article
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia.
- Published in:
- Therapeutic Advances in Psychopharmacology, 2023, p. 1, doi. 10.1177/20451253231200258
- By:
- Publication type:
- Article
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
- Published in:
- CNS Drugs, 2023, v. 37, n. 8, p. 715, doi. 10.1007/s40263-023-01026-3
- By:
- Publication type:
- Article
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia.
- Published in:
- International Journal of Neuropsychopharmacology, 2023, n. 8, p. 537, doi. 10.1093/ijnp/pyad028
- By:
- Publication type:
- Article
Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD.
- Published in:
- International Journal of Neuropsychopharmacology, 2023, v. 26, n. 3, p. 198, doi. 10.1093/ijnp/pyac081
- By:
- Publication type:
- Article
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia.
- Published in:
- Therapeutic Advances in Psychopharmacology, 2023, v. 13, p. 1, doi. 10.1177/20451253231200258
- By:
- Publication type:
- Article
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections.
- Published in:
- Neuropsychiatric Disease & Treatment, 2022, v. 18, p. 1927, doi. 10.2147/NDT.S373725
- By:
- Publication type:
- Article
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials.
- Published in:
- Neuropsychiatric Disease & Treatment, 2021, v. 17, p. 3459, doi. 10.2147/NDT.S339090
- By:
- Publication type:
- Article
Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression.
- Published in:
- Acta Psychiatrica Scandinavica, 2021, v. 143, n. 3, p. 253, doi. 10.1111/acps.13260
- By:
- Publication type:
- Article
Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate.
- Published in:
- Neuropsychiatric Disease & Treatment, 2021, v. 17, p. 1, doi. 10.2147/NDT.S278298
- By:
- Publication type:
- Article
Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
- Published in:
- Early Intervention in Psychiatry, 2020, v. 14, n. 4, p. 428, doi. 10.1111/eip.12868
- By:
- Publication type:
- Article
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
- Published in:
- International Journal of Neuropsychopharmacology, 2020, v. 23, n. 7, p. 426, doi. 10.1093/ijnp/pyaa027
- By:
- Publication type:
- Article
Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.
- Published in:
- Innovations in Clinical Neuroscience, 2020, v. 17, n. 1/3, p. 14
- By:
- Publication type:
- Article
Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia.
- Published in:
- Early Intervention in Psychiatry, 2019, v. 13, n. 3, p. 667, doi. 10.1111/eip.12685
- By:
- Publication type:
- Article
S32. EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA WITH LOW, MODERATE, AND HIGH RECENT DISEASE ACTIVITY AT BASELINE.
- Published in:
- Schizophrenia Bulletin, 2019, v. 45, p. S317, doi. 10.1093/schbul/sbz020.577
- By:
- Publication type:
- Article
Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.
- Published in:
- Neuropsychiatric Disease & Treatment, 2019, v. 15, p. 731, doi. 10.2147/NDT.S194264
- By:
- Publication type:
- Article
Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modification.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 1, p. 22, doi. 10.1002/pst.1905
- By:
- Publication type:
- Article
Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.
- Published in:
- Schizophrenia Bulletin, 2018, v. 44, n. 6, p. 1204, doi. 10.1093/schbul/sbx163
- By:
- Publication type:
- Article
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2018, v. 14, p. 1107, doi. 10.2147/NDT.S157399
- By:
- Publication type:
- Article
Global sensitivity analysis for repeated measures studies with informative drop‐out: A semi‐parametric approach.
- Published in:
- Biometrics, 2018, v. 74, n. 1, p. 207, doi. 10.1111/biom.12729
- By:
- Publication type:
- Article
Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder.
- Published in:
- Psychopharmacology Bulletin, 2017, v. 47, n. 3, p. 8
- By:
- Publication type:
- Article
Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study.
- Published in:
- Neuropsychiatric Disease & Treatment, 2016, v. 9, p. 15, doi. 10.2147/NDT.S83651
- By:
- Publication type:
- Article
The Direct and Indirect Effects of Paliperidone Extended-release on Depressive Symptoms in Schizoaffective Disorder: A Path Analysis.
- Published in:
- Innovations in Clinical Neuroscience, 2015, v. 12, n. 11/12, p. 10
- By:
- Publication type:
- Article
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.
- Published in:
- BMC Psychiatry, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-244X-14-52
- By:
- Publication type:
- Article
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies.
- Published in:
- Annals of General Psychiatry, 2013, v. 12, n. 1, p. 22, doi. 10.1186/1744-859X-12-22
- By:
- Publication type:
- Article
Development and Psychometric Evaluation of a Clinical Global Impression for Schizoaffective Disorder Scale.
- Published in:
- Innovations in Clinical Neuroscience, 2012, v. 9, n. 1, p. 15
- By:
- Publication type:
- Article
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.
- Published in:
- Neuropsychiatric Disease & Treatment, 2012, v. 8, p. 375, doi. 10.2147/NDT.S32581
- By:
- Publication type:
- Article
Use of a Relapse Monitoring Board: An Independent Assessment for Determining Relapse in Clinical Trials for Bipolar Disorder.
- Published in:
- Innovations in Clinical Neuroscience, 2011, v. 8, n. 10, p. 19
- By:
- Publication type:
- Article
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
- Published in:
- BMC Psychiatry, 2011, v. 11, n. 1, p. 21, doi. 10.1186/1471-244X-11-21
- By:
- Publication type:
- Article
Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
- Published in:
- Early Intervention in Psychiatry, 2010, v. 4, n. 1, p. 64, doi. 10.1111/j.1751-7893.2010.00165.x
- By:
- Publication type:
- Article
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
- Published in:
- Bipolar Disorders, 2009, v. 11, n. 8, p. 827, doi. 10.1111/j.1399-5618.2009.00761.x
- By:
- Publication type:
- Article
Psychometric Evaluation of a Patient-Rated Troubling Symptom Scale for Generalized Anxiety Disorder Clinical Trials.
- Published in:
- Psychopharmacology Bulletin, 2008, v. 41, n. 3, p. 68
- By:
- Publication type:
- Article
Risperidone for treatment-refractory major depressive disorder: a randomized trial.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Risperidone for Treatment-Refractory Major Depressive Disorder.
- Published in:
- Annals of Internal Medicine, 2007, v. 147, n. 9, p. 593, doi. 10.7326/0003-4819-147-9-200711060-00003
- By:
- Publication type:
- Article
Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial.
- Published in:
- Psychopharmacology Bulletin, 2007, v. 40, n. 3, p. 41
- By:
- Publication type:
- Article
Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation.
- Published in:
- 2007
- By:
- Publication type:
- Correction notice
Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation.
- Published in:
- Neuropsychopharmacology, 2006, v. 31, n. 11, p. 2505, doi. 10.1038/sj.npp.1301113
- By:
- Publication type:
- Article
Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation.
- Published in:
- 2006
- By:
- Publication type:
- Correction notice
LETTERS TO THE EDITOR Risperidone in the Treatment of Elderly Patients with Psychosis of Alzheimer's Disease and Related Dementias.
- Published in:
- 2004
- By:
- Publication type:
- Letter